Last reviewed · How we verify
LAM group
LAM group refers to a class of compounds targeting lymphangioleiomyomatosis-related pathways, likely inhibiting mTOR signaling to reduce abnormal smooth muscle cell proliferation.
LAM group refers to a class of compounds targeting lymphangioleiomyomatosis-related pathways, likely inhibiting mTOR signaling to reduce abnormal smooth muscle cell proliferation. Used for Lymphangioleiomyomatosis (LAM).
At a glance
| Generic name | LAM group |
|---|---|
| Also known as | Lamivudine |
| Sponsor | GlaxoSmithKline |
| Drug class | mTOR inhibitor |
| Target | mTOR |
| Modality | Small molecule |
| Therapeutic area | Rare Pulmonary/Oncology |
| Phase | Phase 3 |
Mechanism of action
Lymphangioleiomyomatosis (LAM) is a rare lung disease characterized by uncontrolled proliferation of smooth muscle-like cells. LAM group compounds are believed to work by inhibiting the mTOR pathway, which is dysregulated in LAM due to TSC1/TSC2 mutations, thereby suppressing aberrant cell growth and proliferation in the lungs and other affected tissues.
Approved indications
- Lymphangioleiomyomatosis (LAM)
Common side effects
- Immunosuppression/increased infection risk
- Stomatitis
- Diarrhea
- Fatigue
Key clinical trials
- The DECIDE-TB Trial; Validation of Treatment Decision Algorithms for Childhood Tuberculosis (NA)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Immersive Virtual Reality for Respiratory System Physical Examination Training Compared With Peer-Assisted Small-Group Practice: A Randomized Controlled Trial (NA)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients. (PHASE2)
- A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LAM group CI brief — competitive landscape report
- LAM group updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI